Biospecimen and Pathology Core

摘要 Roswell Park卵巢癌孢子生物学和病理学核心(BPC)结合了一个集中的 用于专家组织处理服务的机制和基于组织的分析的性能由高度合格的、 经验丰富的人员，拥有最先进的集成信息基础设施，可为 追踪样本的生物样本收集、组织病理学评估和临床注释，与 免疫基因组学和其他翻译数据由本报告中建议的个别研究项目生成 续签申请。核心将收集、识别、处理、存储和分发带注释的高质量 参与孢子赞助临床研究的患者的肿瘤和血液样本。此外，BPC 将为调查人员提供专门的技术和解释性组织病理学服务，包括 擅长多重免疫组织化学(IHC)和成像质量细胞术(IMC)、组织芯片 构建，激光捕获显微解剖，数字成像，以及切片、肿瘤的定量病理回顾- 浸润性淋巴细胞评估、组织QC/QA和基于下一代测序的分析准备 (整个外显子组序列、RNAseq、TCRseq、甲基SEQ)，并监督每种生物样品的最佳利用。 核心还将在测试患者生物标本方面发挥作用，以确定是否符合临床试验和 通过对卵巢肿瘤的详细免疫学注释，直接添加到双向翻译科学。

ABSTRACT The Roswell Park Ovarian Cancer SPORE Biospecimen & Pathology Core (BPC) combines a centralized mechanism for expert tissue handling services and performance of tissue-based assays by highly qualified, experienced personnel with a state-of-the-art integrated informatics infrastructure which provides tools for tracking biospecimen collection, histopathological evaluation, and clinical annotation of samples with linkage to immunogenomic and other translational data generated by the Individual Research Projects proposed in this renewal application. The Core will collect, de-identify, process, bank, and distribute annotated, high-quality tumor and blood samples from patients participating in SPORE-sponsored clinical studies. In addition, the BPC will provide investigators with specialized technical and interpretative histopathology services including expertise in multiplexed immunohistochemistry (IHC) and imaging mass cytometry (IMC), tissue microarray construction, laser capture microdissection, digital imaging, and quantitative pathology review of slides, tumor- infiltrating lymphocytes assessment, tissue QC/QA and preparation for next-gen sequencing-based assays (whole exome seq, RNAseq, TCRseq, MethylSEQ), and oversight on optimal utilization of each biospecimen. The Core will also be instrumental in testing patient biospecimens to determine eligibility for clinical trials and directly add to the bi-directional translational science by a detailed immunological annotation of ovarian tumors.